title: Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
abstract: BACKGROUND
  Interferon beta (IFNbeta) reduces relapses and MRI activity in relapsing-remitting MS (RRMS), with variable effects on disability. The most effective dose regimen remains controversial.
  
  
  METHODS
  This randomized, controlled, multicenter trial compared the efficacy and safety of IFNbeta-1a (Rebif) 44 micro g subcutaneously three times weekly (tiw), and IFNbeta-1a (Avonex) 30 micro g IM once weekly (qw) in 677 patients with RRMS. Assessors blinded to treatment performed neurologic and MRI evaluations. The primary endpoint was the proportion of patients who were relapse free at 24 weeks; the principal MRI endpoint was the number of active lesions per patient per scan at 24 weeks.
  
  
  RESULTS
  After 24 weeks, 74.9% (254/339) of patients receiving IFNbeta-1a 44 micro g tiw remained relapse free compared with 63.3% (214/338) of those given 30 micro g qw. The odds ratio for remaining relapse free was 1.9 (95% CI, 1.3 to 2.6; p = 0.0005) at 24 weeks and 1.5 (95% CI, 1.1 to 2.1; p = 0.009) at 48 weeks, favoring 44 micro g tiw. Patients receiving 44 micro g tiw had fewer active MRI lesions (p < 0.001 at 24 and 48 weeks) compared with those receiving 30 micro g qw. Injection-site reactions were more frequent with 44 micro g tiw (83% vs 28%, p < 0.001), as were asymptomatic abnormalities of liver enzymes (18% vs 9%, p = 0.002) and altered leukocyte counts (11% vs 5%, p = 0.003) compared with the 30 micro g qw dosage. Neutralizing antibodies developed in 25% of 44 micro g tiw patients and in 2% of patients receiving 30 micro g qw.
  
  
  CONCLUSIONS
  IFNbeta-1a 44 micro g subcutaneously tiw was more effective than IFNbeta-1a 30 micro g IM qw on all primary and secondary outcomes investigated after 24 and 48 weeks of treatment.
authors.affiliation: University of Vermont College of Medicine, Burlington, VT 05401, USA. hillel.panitch@vtmednet.org
authors.forename: H
authors.initials: H
authors.lastname: Panitch
authors.forename: D S
authors.initials: DS
authors.lastname: Goodin
authors.forename: G
authors.initials: G
authors.lastname: Francis
authors.forename: P
authors.initials: P
authors.lastname: Chang
authors.forename: P K
authors.initials: PK
authors.lastname: Coyle
authors.forename: P
authors.initials: P
authors.lastname: O'Connor
authors.forename: E
authors.initials: E
authors.lastname: Monaghan
authors.forename: D
authors.initials: D
authors.lastname: Li
authors.forename: B
authors.initials: B
authors.lastname: Weinshenker
mesh_terms: D000293:Adolescent; D000328:Adult; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007958:Leukocyte Count; D008111:Liver Function Tests; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology; D011153:Population; D012008:Recurrence; D018401:Sample Size; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D016899:Interferon-beta; D000068556:Interferon beta-1a